Semglee is Interchangeable with Lantus
Yes, Semglee (insulin glargine-yfgn) is FDA-designated as interchangeable with Lantus (insulin glargine) and can be substituted at the pharmacy without prescriber notification in accordance with state laws. 1
Regulatory Status and Substitution
Semglee became the first interchangeable biosimilar insulin in the United States in July 2021 1, 2. This interchangeable designation means:
- Pharmacists can substitute Semglee for Lantus at the point of sale without contacting the prescriber, following state-specific substitution laws 1, 2
- The FDA determined Semglee is "highly similar" to Lantus with "no clinically meaningful differences" 1
- Both products contain insulin glargine 100 units/mL (U-100) concentration 3, 1
Clinical Equivalence Evidence
The INSTRIDE clinical trial program demonstrated:
- Non-inferiority for glucose reduction between Semglee and Lantus 2
- Comparable adverse effect profiles 2
- INSTRIDE 3 specifically tested switching between products multiple times during the trial without statistically significant changes in glucose control or adverse effects 2
This switching data was critical for achieving interchangeable status and confirms safety when patients transition between products.
Practical Considerations for Prescribers
Dosing conversion is straightforward: Unit-for-unit substitution with no dose adjustment needed when switching between Lantus and Semglee 3, 1. Both are:
- Administered subcutaneously once daily at the same time each day
- Injected into abdomen, thigh, or deltoid
- Clear, colorless solutions that should never be mixed or diluted
State law variations matter: While FDA approval permits substitution, individual state pharmacy laws govern whether automatic substitution occurs 4. States with less restrictive substitution laws show significantly higher Semglee adoption (20.6% vs 12.1% market share) 4. Enhanced physician notification requirements, refill notifications, and patient notification requirements in some states reduce biosimilar uptake 4.
Safety Profile
Post-marketing surveillance through FDA Adverse Event Reporting System shows:
- No significant safety signals for serious adverse events, death, or hospitalization for either product 5
- Both products share expected insulin glargine adverse events: hypoglycemia, hyperglycemia, weight changes, lipodystrophy 5
- Semglee shows higher reporting of device issues and product quality concerns, likely reflecting increased scrutiny as a new product rather than true safety differences 5
Cost and Access Benefits
Semglee's list price is significantly lower than Lantus 2. The interchangeable designation has driven:
- Increased market competition reducing costs of all insulin glargine products 2
- Improved insurance coverage, particularly in employer-sponsored plans (19.25 percentage point increase in market share) 6
- Enhanced access for patients previously unable to afford insulin therapy 2
Common Pitfalls to Avoid
Do not adjust doses when switching: Unlike switching between some basal insulins (e.g., detemir to glargine may require 10-20% dose reduction), Lantus and Semglee are truly unit-for-unit interchangeable 7, 3, 1
Patient education is essential: Inform patients that pharmacy substitution may occur and that this is FDA-approved and safe. Confusion about biosimilars can reduce adherence 2
Check your state's substitution laws: Automatic substitution may not occur in all states, potentially requiring you to prescribe Semglee specifically if cost is a concern for your patient 4
Both products cannot be mixed or diluted: This applies equally to Lantus and Semglee—mixing destroys the pharmacokinetic profile 3, 1